Determination of talinolol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry: Application to pharmacokinetic study

被引:6
作者
He Juan
Terhaag, Bernd
Yang Li-Ying
Zhang Bi-Kui
Su Fen-Li
Zhu Yun-Gui
Song Juan
Tang Jing
Liu Xiao-Lei
Peng Wen-Xing [1 ]
机构
[1] Cent S Univ, Second Xiangya Hosp, Clin Pharm & Pharmacol Inst, Changsha 410011, Peoples R China
[2] Arzneimittelwerk Dresden GmbH, D-01445 Radebeul, Germany
[3] Hosp Tsing Hua Univ, Dept Pharmaceut, Beijing 100084, Peoples R China
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2007年 / 853卷 / 1-2期
关键词
talinolol; pharmacokinetics; HPLC-MS/ESI;
D O I
10.1016/j.jchromb.2007.03.035
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A rapid and sensitive method for determination and screening in human plasma of talinolol is described using propranolol as the internal standard. The analytes in plasma were extracted by liquid-liquid extraction using methyl t-butyl ether. After removed and dried the upper organic phase, the extracts were reconstituted with a fixed volume of buffer of ammonium acetate and acetonitrile (60:40, v/v). The extracts were analyzed by a HPLC coupled to electrospray ionization mass spectrometry (HPLC-MS/ESI). The HPLC separation of the analytes was performed on a Phenomenex C 18 (250 mm x 4.6 mm, 5 mu m, USA) column, with a flow rate of 0.85 mL/mm. The complete elution was obtained within 5.5 min. The calibration curve was linear in the 1.0-400.0 ng/mL range for talinolol, with a coefficient of determination of 0.9996. The average extraction recovery was above 83%. The methodology recovery was between 101% and 102%. The limit of detection (LOD) was 0.3 ng/mL for talinolol. The intraday and inter-day coefficients of variation were less than 6%. This HPLC-MS/ESI procedure was used to assess the pharmacokinetics of talinolol. A single oral 50 mg dose of talinolol tablet was administered to 12 healthy Chinese volunteers, the main pharmacokinetic data are as follows: Cm, was 147.8 +/- 63.8 ng/mL; t(max) was 2.0 +/- 0.7 h; t(1/2) was 12.0 +/- 2.6 h. The method is accurate, sensitive and simple for the pharmacokinetic study of talinolol. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:275 / 280
页数:6
相关论文
共 30 条
[1]  
Assmann I, 1995, CURR MED RES OPIN, V13, P325
[2]   The cardiac insufficiency talinolol study (CITAS) study design [J].
Campeanu, A .
EUROPEAN JOURNAL OF HEART FAILURE, 2001, 3 (03) :377-380
[3]  
CAMPEANU A, 1999, CARDIOVASC DRUG THER, V263, P131
[4]  
CAMPEANU A, 1999, CARDIOVASC DRUG THER, V68, P131
[5]   The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability [J].
Chan, LMS ;
Lowes, S ;
Hirst, BH .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 21 (01) :25-51
[6]   The complexities of hepatic drug transport: Current knowledge and emerging concepts [J].
Chandra, P ;
Brouwer, KLR .
PHARMACEUTICAL RESEARCH, 2004, 21 (05) :719-735
[7]  
EMMANUEL B, 2005, J CHROMATOGR B, V820, P103
[8]   Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans [J].
Giessmann, T ;
May, K ;
Modess, C ;
Wegner, D ;
Hecker, U ;
Zschiesche, M ;
Dazert, P ;
Grube, M ;
Schroeder, E ;
Warzok, R ;
Cascorbi, I ;
Kroemer, HK ;
Siegmund, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (03) :192-200
[9]   Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans [J].
Gramatte, T ;
Oertel, R ;
Terhaag, B ;
Kirch, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (05) :541-549
[10]   Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3) [J].
Jonker, JW ;
Schinkel, AH .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (01) :2-9